National Institute of Health
COPAXONE-BAD NEWS,,,STUDY...Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing MS
"INTERPRETATION: 5 mg and 50 mg glatiramer acetate administered orally on a daily basis do not affect relapse rate or other clinical and MRI parameters of disease activity and burden in patients with relapsing-remitting multiple sclerosis. Treatment with oral formulations of glatiramer acetate at the doses tested cannot be recommended"